An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Conditions
- Ovary Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
- DRUG: Mirvetuximab Soravtansine-gynx
- DRUG: Olaparib
Sponsor
University of Colorado, Denver
Collaborators